Common use of Generic Competition Clause in Contracts

Generic Competition. (a) If, during a given calendar year, there is sale of a generic Sphingosomal Vinorelbine or sale of an approved equivalent to Sphingosomal Vinorelbine (collectively, “Approved Sphingosomal Vinorelbine Equivalents”) in any country in the Territory, then, for such country, the total amount of royalties payable to INEX for the Net Sales of Sphingosomal Vinorelbine in such country during such calendar year will be reduced to [*] of the royalties payable to INEX pursuant to Section 3.2.2 for such calendar year, in such country.

Generic Competition. (a) If, during a given calendar year, there is sale of a generic Sphingosomal Vinorelbine Vincristine or sale of an approved equivalent to Sphingosomal Vinorelbine Vincristine (collectively, “Approved Sphingosomal Vinorelbine Vincristine Equivalents”) in any country in the Territory, then, for such country, the total amount of royalties payable to INEX for the Net Sales of Sphingosomal Vinorelbine Vincristine in such country during such calendar year will be reduced to [*] of the royalties payable to INEX pursuant to Section 3.2.2 3.1.2 for such calendar year, in such country.

Generic Competition. (a) If, during a given calendar year, there is sale of a generic Sphingosomal Vinorelbine Topotecan or sale of an approved equivalent to Sphingosomal Vinorelbine Topotecan (collectively, “Approved Sphingosomal Vinorelbine Topotecan Equivalents”) in any country in the Territory, then, for such country, the total amount of royalties payable to INEX for the Net Sales of Sphingosomal Vinorelbine Topotecan in such country during such calendar year will be reduced to by [*] of the royalties payable to INEX pursuant to Section 3.2.2 3.3.2 for such calendar year, in such country.

Generic Competition. (a) If, during a given calendar year, there is sale of a generic Sphingosomal Vinorelbine or sale of an approved equivalent to Sphingosomal Vinorelbine (collectively, “Approved Sphingosomal Vinorelbine Equivalents”) in any country in the Territory, then, for such country, the total amount of royalties payable to INEX for the Net Sales of Sphingosomal Vinorelbine in such country during such calendar year will be reduced to [***] percent ([***]%) of the royalties payable to INEX pursuant to Section 3.2.2 for such calendar year, in such country.

Generic Competition. (a) If, during a given calendar year, there is sale of a generic Sphingosomal Vinorelbine or sale of an approved equivalent to Sphingosomal Vinorelbine (collectively, “Approved Sphingosomal Vinorelbine Equivalents”) in any country in the Territory, thenthem, for such country, the total amount of royalties payable to INEX for the Net Sales of Sphingosomal Vinorelbine in such country during such calendar year will be reduced to [***] percent ([***]%) of the royalties payable to INEX pursuant to Section 3.2.2 for such calendar year, in such country.

Generic Competition. (a) If, during a given calendar year, there is sale of a generic Sphingosomal Vinorelbine or sale of an approved equivalent to Sphingosomal Vinorelbine (collectively, “Approved Sphingosomal Vinorelbine Equivalents”) in any country in the Territory, thenthem, for such country, the total amount of royalties payable to Royalties Due INEX for the Net Sales of Sphingosomal Vinorelbine in such country during such calendar year will be reduced to [***] percent ([***]%) of the royalties payable to Royalties Due INEX pursuant to Section 3.2.2 5.7(b)(ii) for such calendar year, in such country.

Generic Competition. (a) If, during a given calendar year, there is sale of a generic Sphingosomal Vinorelbine Vincristine or sale of an approved equivalent to Sphingosomal Vinorelbine Vincristine (collectively, “Approved Sphingosomal Vinorelbine Vincristine Equivalents”) in any country in the Territory, then, for such country, the total amount of royalties payable to INEX for the Net Sales of Sphingosomal Vinorelbine Vincristine in such country during such calendar year will be reduced to [***] percent ([***]%) of the royalties payable to INEX pursuant to Section 3.2.2 3.1.2 for such calendar year, in such country.

Generic Competition. (a) If, during a given calendar year, there is sale of a generic Sphingosomal Vinorelbine Vincristine or sale of an approved equivalent to Sphingosomal Vinorelbine Vincristine (collectively, “Approved Sphingosomal Vinorelbine Vincristine Equivalents”) in any country in the Territory, then, for such country, the total amount of royalties payable to INEX for the Net Sales of Sphingosomal Vinorelbine Vincristine in such country during such calendar year will be reduced to [***] percent ([***]%) of the royalties payable to INEX pursuant to Section 3.2.2 3.1.2 for such calendar year, in such country.